Resistance to Calcitonin

  • Frederick R. Singer
  • Karla Ginger


For more than 20 years, calcitonin has been used in the treatment of Paget’s disease. With long-term administration of the hormone, two main patterns of biochemical response have been observed.1 In most patients, serum alkaline phosphatase activity and urinary hydroxyproline excretion fall over a period of months and reach a plateau at an average reduction of about 50% below pretreatment levels. Biochemical indexes may remain suppressed to this degree for more than 10 years as treatment continues (Figure 7.1). In a smaller group of patients after an initial period of typical biochemical suppression, the indices gradually rise, and with continuing treatment they reach pretreatment or even higher levels (Figure 7.2). This latter pattern of acquired clinical resistance appears to occur most commonly when salmon or porcine calcitonin is administered, but a similar clinical course has been observed in a few patients on human calcitonin therapy. Primary clinical resistance may occur but appears to be unusual.


Salmon Calcitonin Clinical Resistance Calcitonin Receptor Human Calcitonin Serum Alkaline Phosphatase Activity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Singer FR, Keutman HT, Neer RM, et al: Pharmacological effects of salmon calcitonin in man, in Talmage RV, Munson PL (eds): Calcium, Parathyroid Hormone and the Calcitonins. Amsterdam, Excerpta Medica Foundation, 1972, pp 89–96.Google Scholar
  2. 2.
    Singer FR, Aldred JP, Neer RM, et al: An evaluation of antibodies and clinical resistance to salmon calcitonin. J Clin Invest 1972; 51: 2331–2338.PubMedCrossRefGoogle Scholar
  3. 3.
    Haddad JG Jr, Caldwell JG: Calcitonin resistance: Clinical and immunologic studies in subjects with Paget’s disease of bone treated with porcine and salmon calcitonins. J Clin Invest 1972; 51: 3133–3141.PubMedCrossRefGoogle Scholar
  4. 4.
    Dube WJ, Goldsmith RS, Arnaud SB, et al: Development of antibodies to porcine calcitonin during treatment of Paget’s disease of bone. Mayo Clin Proc 1973; 48: 43–46.PubMedGoogle Scholar
  5. 5.
    DeRose J, Singer FR, Avramides A, et al: Response of Paget’s disease to porcine and salmon calcitonins. Am J Med 1974; 56: 858–866.PubMedCrossRefGoogle Scholar
  6. 6.
    Plehwe WE, Hudson J, Clifton-Bligh P, et al: Porcine calcitonin in the treatment of Paget’s disease of bone. Med J Aust 1977; 1: 577–581.PubMedGoogle Scholar
  7. 7.
    Woodhouse NJY, Mohamedally SM, Saed-Nejad F, et al: Development and significance of antibodies to salmon calcitonin in patients with Paget’s disease in long-term treatment. Br Med J 1977; 9: 927–929.CrossRefGoogle Scholar
  8. 8.
    Martin TJ, Jerums G, Melick RA, et al: Clinical, biochemical and histological observations on the effect of porcine calcitonin in Paget’s disease of bone. Aust NZ J Med 1977; 7: 36–43.CrossRefGoogle Scholar
  9. 9.
    Hosking DJ, Denton LB, Cadge B, et al: Functional significance of antibody formation after long-term salmon calcitonin therapy. Clin Endocrinol 1979; 10: 243–252.CrossRefGoogle Scholar
  10. 10.
    Azria M: The calcitonins. In Physiology and Pharmacology. Basel, Karger, 1989.Google Scholar
  11. 11.
    Levy F, Muff R, Dotti-Sigrist S, et al: Formation of neutralizing antibodies during intranasal synthetic salmon calcitonin treatment of Paget’s disease. J Clin Endocrinol Metab 1988; 67: 541–545.PubMedCrossRefGoogle Scholar
  12. 12.
    Grauer A, Friedhelm R, Schneider H, et al: In vitro detection of neutralizing antibodies after treatment of Paget’s disease of bone with nasal salmon calcitonin. J Bone Mineral Res 1990; 5: 387–391.CrossRefGoogle Scholar
  13. 13.
    D’Agostino HR, Barnett CA, Zielinski XJ, et al: Intranasal salmon calcitonin treatment of Paget’s disease of bone. Clin Orthop 230: 223–228.Google Scholar
  14. 14.
    Singer FR, Villanueva R, Ginger K: Acquired resistance to salmon and human calcitonin during treatment of Paget’s disease of bone. Calcif Tissue Int 1989; 44 (suppl): S87.Google Scholar
  15. 15.
    Nagant de Deuxchaisnes C, Devogelaer JP: Alternative modes of administration of salmon calcitonin as assessed in Paget’s disease of bone. In Singer FR, Wallach S (eds): Paget’s Disease of Bone: Clinical Assessment, Present and Future Therapy. New York, Elsevier Science Publishing Co, 1991, pp 135–165.Google Scholar
  16. 16.
    Rojanasathit S, Rosenberg E, Haddad JG Jr: Paget’s bone disease: Response to human calcitonin in patients resistant to salmon calcitonin. Lancet 1974; 2: 1412–1415.PubMedCrossRefGoogle Scholar
  17. 17.
    Singer FR, Fredericks RS, Minkin C: Salmon calcitonin therapy for Paget’s disease of bone: The problem of acquired clinical resistance. Arthritis Rheum 1980; 23: 1148–1154.PubMedCrossRefGoogle Scholar
  18. 18.
    Muff R, Dambacher MA, Perrenoud A, et al: Efficacy of intranasal human calcitonin in patients with Paget’s disease refractory to salmon calcitonin. Am J Med 1990; 89: 181–184.PubMedCrossRefGoogle Scholar
  19. 19.
    Lo Cascio V, Adami S, Galvanini G, et al: Response of Paget’s disease to human calcitonin in patients resistant to porcine calcitonin. J Endocrinol Invest 1984; 7: 85–88.PubMedGoogle Scholar
  20. 20.
    Martin TJ: Treatment of Paget’s disease with calcitonins. Aust NZ J Med 1979; 9: 36–43.CrossRefGoogle Scholar
  21. 21.
    Reginster JY, Gennari C, Mautalen C, et al: Influence of specific anti-salmon calcitonin antibodies on biological effectiveness of nasal salmon calcitonin in Paget’s disease of bone. Scand J Rheumatol 1990; 19: 83–86.PubMedCrossRefGoogle Scholar
  22. 22.
    Avramides A, Flores A, DeRose J, et al: Paget’s disease of the bone: Observations after cessation of long-term synthetic salmon calcitonin treatment. J Clin Endocrinol Metab 1976; 42: 459–463.PubMedCrossRefGoogle Scholar
  23. 23.
    Dietrich FM, Fischer JA, Bijvoet OLM: Formation of antibodies to synthetic human calcitonin during treatment of Paget’s disease. Acta Endocrinol 1979; 92: 468–476.PubMedGoogle Scholar
  24. 24.
    Singer FR, Ahrne-Collier I: Salmon calcitonin therapy: Antibodies and clinical resistance in patients with Paget’s disease of bone. In Maclntyre I, Szelke M (eds): Molecular Endocrinology. Amsterdam, Elsevier/North Holland Biomedical Press, 1977, pp 207–212.Google Scholar
  25. 25.
    Maclntyre I, Evans IMA, Hobitz HG, et al: Chemistry, physiologic and therapeutic applications of calcitonin. Arthritis Rheum 1980; 23: 1139–1147.CrossRefGoogle Scholar
  26. 26.
    Singer FR, Rude RK, Mills BG: Studies in the treatment and etiology of Paget’s disease of bone, in Maclntyre I (ed): International Symposium on Human Calcitonin and Paget’s Disease. Bern, Stuttgart, Vienna, Hans Huber Publishers, 1977, p. 93.Google Scholar

Copyright information

© Elsevier Science Publishing Co., Inc. 1991

Authors and Affiliations

  • Frederick R. Singer
  • Karla Ginger

There are no affiliations available

Personalised recommendations